The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: an examination of the available evidence
AffiliationThe University of Manchester, Faculty of Biology, Medicine and Health Department of Endocrinology
MetadataShow full item record
AbstractPurpose of review: Coronavirus Disease 2019 (COVID19) has caused significant global morbidity and mortality, especially in persons with underlying cardiovascular disease. There have been concerns that lipid-lowering therapy (LLT) increases angiotensin-converting enzyme 2 levels. Conversely, pleiotropic effects of statins can theoretically protect against severe COVID19 infection, supporting evidence from other respiratory illnesses in which statin use probably confers benefit. Recent findings: There is an abundance of studies that show that statins are safe and potentially protect against severe COVID19 infection (critical illness and death), even when adjustment for potential confounders is undertaken. However, the evidence is limited to retrospective cohorts. The benefit for patients with diabetes is less clear. There is a paucity of evidence for other LLT agents. Available clinical guidelines recommend the ongoing use of LLT in patients with COVID19 (unless specifically contra-indicated) and the data from available studies support these. Summary: In patients with COVID19 infection, LLT should be continued. However, the current findings need substantiating in larger prospective clinical studies with specific examination of the possible mechanisms by which LLT confers benefit from COVID19.
CitationAdam S, Ho JH, Bashir B, Iqbal Z, Ferdousi M, Syed AA, et al. The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: an examination of the available evidence. Current Opinion in Lipidology . 2021 Jun 9;32(4):231–43.
JournalCurrent Opinion in Lipidology
- The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
- Authors: Tan NC, Goh CC, Goh SC, Koh YL, Koh KH
- Issue date: 2016 Dec
- Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
- Authors: Tenenbaum A, Fisman EZ, Motro M, Adler Y
- Issue date: 2008
- A Clinical Guide to Combination Lipid-Lowering Therapy.
- Authors: Russell C, Sheth S, Jacoby D
- Issue date: 2018 Mar 7
- Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
- Authors: Morieri ML, Avogaro A, Fadini GP, the DARWIN-T2D Network of the Italian Diabetes Society.
- Issue date: 2020 Nov 10
- Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
- Authors: Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, Li Z, Wei Y, Ambegaonakr BM, Hu D, DYSIS-China Study Investigators.
- Issue date: 2014 Aug